Overview
Nestmedic is a technology company specializing in telemedicine and digital health, focusing on advanced medical diagnostics for pregnant women. It offers the Pregnabit device, which improves access to KTG (cardiotocography) diagnostics while reducing costs for healthcare providers. The company also supports women's health initiatives, including distributing Pregnabit devices to aid pregnant women in Ukraine.
Financials
Revenue history (in k)
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Stock quotes
- Open
- PLN 0.67
- High
- PLN 0.67
- Low
- PLN 0.64
- Volume
- 17K
- Avg. vol.
- 78.16K
- Market cap
- PLN 39.98M
- P/E ratio
- —
- EPS
- -PLN 0.07
- Shares outstanding
- 61.5M
- 52-week
- PLN 0.49 – 0.72
- Dividend yield
- —
- Dividend
- —
- Ex dividend date
- —
- ISIN
- PLNSTMD00010
- Exchange
- NewConnect
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
News
We support women's health in Ukraine
Pregnabit Pro now available in Denmark!
Nestmedic has entered into a distribution agreement for Pregnabit Pro devices and a licence to use the Pregnabit Cloud Platform with the Scandinavian medical market leader ScanMed A/S, based in Denmark. The purpose of the agreement is to grant the distributor the right to distribute and sell Pregnabit Pro devices and the licence to use
Pregnabit Pro now available in Denmark!
Industry
Bank accounts
Registered as a VAT taxpayer on 2014-07-07. Active
32 1090 2428 0000 0001 2370 1440
08 1140 1977 0000 2370 0700 2003- 35 1140 1977 0000 2370 0700 2002
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
Public aid
8 public aid cases recorded, with a total value of $1,460,680.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Sep 20, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | —— | Prezes Zakładu Ubezpieczeń Społecznych | |
| Jul 24, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | —— | Prezes Zakładu Ubezpieczeń Społecznych | |
| Jul 24, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | —— | Prezes Zakładu Ubezpieczeń Społecznych |
European Funds
2 projects recorded: 1 from FE lists ($136,069) and 1 Commission grant (FTS) ($56,352).
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2017-07-01 | Internacjonalizacja innowacyjnego systemu telemedycznego firmy NESTMEDIC na rynkach międzynarodowych | $136.1K$136,069 | Program Operacyjny Inteligentny Rozwój | |
| 2017-02-01 | 761945 - Pregnabit - pregnabit the worlds first complex telemedical mobile ctg system for pregnancy examination | $56,352$56,352 | 1.1.31 - Horizon 2020 |
Tenders
No recorded participation in tenders.
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
 BDO | BDO register entry | Active |
Authorized Representatives
Manner of representation
The persons authorized to represent the company are: in the case of a one-person management board – the President of the Management Board independently; in the case of a multi-member management board – two members of the management board, at least one of whom must always be the President of the Management Board.
Supervisory board
Beneficial owners
No beneficial owners recorded for the company Nestmedic.
Capital group
| Name | Ownership |
|---|---|
| 100% |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Pro-PlusS.A. | $1,116,507.20 | pro-plus.pl | ||
| Mescomp TechnologiesS.A. | $709,799.37 | mescomp.pl | ||
| Silsense TechnologiesS.A. | $444,795.89 | silsense.pl | ||
| Inventmedsp. z o.o. | $73,620.90 | inventmed.pl |
Change history
| Date | Event | |
|---|---|---|
| 2026-08-26 | Share capital change (5,532,689.90 PLN → 6,139,689.90 PLN) | |
| 2026-04-17 | Share capital change (4,311,366.20 PLN → 5,532,689.90 PLN) | |
| 2025-06-09 | Share capital change (3,659,366.20 PLN → 4,311,366.20 PLN) | |
| 2025-05-12 | Share capital change (3,359,366.20 PLN → 3,659,366.20 PLN) | |
| 2025-04-14 | Share capital change (3,204,140.40 PLN → 3,359,366.20 PLN) |
FAQ
Last updated: 2026-08-26